论文信息 - Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience - 字舞流文

Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience

I. Poddubnaya | I. V. Kolyadina | I. Ganshina | S. V. Kuzmicheva | Asiiat I. Tekeeva | James D. Kolokolov | Mikhail V. Volkonskii | M. V. Volkonskii